Testing effectiveness (Phase 2)Study completedNCT02199184
What this trial is testing
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
Who this might be right for
AIDS-Related Burkitt LymphomaAtypical Burkitt/Burkitt-Like LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements+5 more
M.D. Anderson Cancer Center 14